drugset / Trial / NCT01295060

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

NCT01295060

Phase 3 Terminated 12 enrolled Endo USA Inc., a Keenova Therapeutics Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.

Timeline

Start
2011-02
Primary completion
2012-04
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 84 mg Subcutaneous

Indications